Eugean Jiwanmall, MPH, MBA

Recommendations to address limitations in more widespread use of reflex testing in community oncology.

How payers will support the use of comprehensive genomic profiling in oncology moving forward.

Expectations regarding the future utilization of comprehensive genomic profiling in clinical practice to assess patients with solid tumor cancers.

Payer perspective regarding decisions for covering the costs of molecular assays in oncology and reimbursing oncologists for treatments provided to patients while navigating long turnaround times associated with reflex testing.

Criteria used by payers to determine how to code and support the use of various genomic profiling assays used in oncology.

Payer response to supporting decisions for coverage of comprehensive genomic profiling in oncology.

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

Oncologists who manage patients with solid tumors compare and contrast current comprehensive molecular assays being used in clinical practice and discuss reimbursement criteria with payer, Eugean Jiwanmall, MPH, MBA.

Considerations regarding coverage decisions to support the large amount of information provided by molecular testing assays and the validity of results in terms of clinical decision-making.

Payer perspective regarding updates to coverage for comprehensive genomic profiling, becoming more widely used in oncology practice.